Wockhardt
Ticker > Company >

Wockhardt share price

Wockhardt Ltd.

NSE: WOCKPHARMA BSE: 532300 SECTOR: Pharmaceuticals & Drugs  93k   206   37

1230.95
+58.60 (5.00%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 1230.95

Today's Low

₹ 1171

52 Week High

₹ 1334.55

52 Week Low

₹ 323.3

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 19999.53 Cr.

Enterprise Value

₹ 21303.53 Cr.

No. of Shares

16.25 Cr.

P/E

0

P/B

7.23

Face Value

₹ 5

Div. Yield

0 %

Book Value (TTM)

₹  170.17

CASH

₹ 486 Cr.

DEBT

₹ 1790 Cr.

Promoter Holding

51.99 %

EPS (TTM)

₹  -14.16

Sales Growth

7.65%

ROE

-23.98 %

ROCE

-5.32%

Profit Growth

9.44 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year7.65%
3 Year5.35%
5 Year-5.82%

Profit Growth

1 Year9.44%
3 Year-189.28%
5 Year-225.82%

ROE%

1 Year-23.98%
3 Year-18.37%
5 Year-23.22%

ROCE %

1 Year-5.32%
3 Year-3.57%
5 Year-6.68%

Debt/Equity

1.0039

Price to Cash Flow

106.38

Interest Cover Ratio

-0.7806

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 51.99 33.64
Jun 2024 51.99 37.47
Mar 2024 51.60 52.90
Dec 2023 54.93 74.51
Sep 2023 55.14 64.38
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -165.7865 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 8.94236210679695.

 Limitations

  • The company has shown a poor profit growth of -2.6190139336997% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.34873516334839% for the Past 3 years.
  • Company has a poor ROE of -18.369805903146% over the past 3 years.
  • Company has a poor ROCE of -3.56601620376964% over the past 3 years
  • Company has low Interest coverage ratio of -0.7806.
  • Company has contingent liabilities of 882.46 Cr.
  • The company has a low EBITDA margin of -2.82871602225512% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 118.5168.
  • Promoter pledging is high as 33.64%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 260 288 355 352 370
Total Expenditure 270 263 401 272 321
Operating Profit -10 25 -46 80 49
Other Income 6 5 24 27 11
Interest 59 61 59 58 53
Depreciation 44 43 45 43 43
Exceptional Items 0 0 0 0 0
Profit Before Tax -107 -74 -126 6 -36
Tax 0 0 0 0 0
Profit After Tax -107 -74 -126 6 -36
Adjusted EPS (Rs) -7.43 -5.14 -8.18 0.39 -2.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 890.06 987 1372 1072 1154
Total Expenditure 1066 1125 1150 1002 1190
Operating Profit -175.94 -138 222 70 -36
Other Income 85.82 41 38 67 41
Interest 220.17 200 273 229 237
Depreciation 173.39 184 171 186 176
Exceptional Items 0 -142 0 -235 -14
Profit Before Tax -483.68 -623 -184 -513 -422
Tax -158 -231 -44 -47 0
Net Profit -231.12 593 -140 -466 -422
Adjusted EPS (Rs.) -27.1 -32.84 -9.72 -32.36 -27.4

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 55.37 55 72 72 77
Total Reserves 939.25 1551 2140 1681 1719
Borrowings 519.5 259 146 12 891
Other N/C liabilities 692.74 272 187 91 43
Current liabilities 2305.25 2603 3049 2626 1888
Total Liabilities 4512.11 4740 5594 4482 4618
Assets
Net Block 2044.35 1684 1828 1625 1449
Capital WIP 305.29 307 69 56 56
Intangible WIP 0 409 756 767 777
Investments 297.27 297 297 297 297
Loans & Advances 202.02 203 238 245 243
Other N/C Assets 85.92 145 162 196 128
Current Assets 1577.26 1695 2244 1296 1668
Total Assets 4512.11 4740 5594 4482 4618
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -338.32 861 -184 -513 -422
Adjustment 355.96 -995 410 433 494
Changes in Assets & Liabilities 204.37 -318 -240 156 116
Tax Paid -0.5 -111 -79 -5 0
Operating Cash Flow 221.51 -563 -93 71 188
Investing Cash Flow -16.15 1014 -244 -3 -75
Financing Cash Flow -273.97 -480 430 -236 346
Net Cash Flow -68.61 -29 93 -168 459

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 55.14 54.93 51.60 51.99 51.99
ananke trustee company pr... 2.73 2.73 2.57 2.66 2.66
callirhoe trustee company... 0.65 0.65 0.61 0.61 0.61
callirhoe trustee company... 1.85 1.85 1.73 2.03 2.03
habil f khorakiwala 0.41 0.41 0.39 0.39 0.39
huzaifa habil khorakiwala... 0.19 0.19 0.18 0.18 0.18
murtaza habil khorakiwala... 0.20 0.20 0.19 0.19 0.19
pasithee trustee company ... 3.52 3.52 3.30 3.30 3.30
themisto trustee company ... 45.58 45.37 42.61 42.61 42.61
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 44.86 45.07 48.40 48.01 48.01
3p india equity fund 1 - - - - 1.47
icici prudential equity &... - - 1.26 1.27 1.27
investor education and pr... 0.16 0.16 0.20 - 0.20
llp 0.26 0.31 0.58 0.47 0.77
rekha jhunjhunwala - - 1.89 1.89 1.85
investor education and pr... - - - 0.20 -
rekha rakesh jhunjhunwala... 2.04 2.04 - - -
neomile corporate advisor... 1.38 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Wockhardt - Quaterly Results 13 Nov, 1:35 PM Wockhardt - Quaterly Results 13 Nov, 1:35 PM Wockhardt - Quaterly Results 13 Nov, 1:35 PM Wockhardt informs about investor presentation 21 Oct, 10:14 AM Wockhardt informs about press release 16 Oct, 10:06 AM Wockhardt informs about press release 7 Oct, 2:12 PM Wockhardt informs about press release 23 Sep, 10:05 AM Wockhardt informs about press release 19 Sep, 11:06 AM Wockhardt informs about loss of share certificates 9 Sep, 5:30 PM Wockhardt informs about issuance of duplicate share certificate 20 Aug, 5:29 PM Wockhardt informs about outcome of board meeting 9 Aug, 5:12 PM Wockhardt - Quaterly Results 9 Aug, 3:04 PM Wockhardt - Quaterly Results 9 Aug, 3:04 PM Wockhardt - Quaterly Results 9 Aug, 3:04 PM Wockhardt informs about compliance certificate 11 Jul, 4:48 PM Wockhardt informs about disclosure of voting results of 25th AGM 2 Jul, 4:33 PM Wockhardt - Quaterly Results 28 May, 7:38 PM Wockhardt - Quaterly Results 28 May, 7:38 PM Wockhardt informs about closure of trading window 19 Mar, 10:13 AM Wockhardt informs about investor presentation 26 Feb, 2:33 PM Wockhardt - Quaterly Results 14 Feb, 2:34 PM Wockhardt - Quaterly Results 14 Feb, 2:34 PM Wockhardt - Quaterly Results 14 Feb, 2:34 PM Wockhardt completes pivotal Phase 3 pneumonia study of Nafithromycin 12 Dec, 11:27 AM Wockhardt informs about press release 11 Dec, 4:44 PM Wockhardt informs about loss of share certificate 22 Nov, 5:26 PM Wockhardt - Quaterly Results 14 Nov, 2:24 PM Wockhardt - Quaterly Results 14 Nov, 2:24 PM Wockhardt - Quaterly Results 14 Nov, 2:24 PM Wockhardt’s consolidated net loss widens to Rs 136 crore in Q1 14 Aug, 4:23 PM Wockhardt - Quaterly Results 14 Aug, 2:25 PM Wockhardt - Quaterly Results 14 Aug, 2:25 PM Wockhardt - Quaterly Results 14 Aug, 2:25 PM Wockhardt aims to turnaround business operations 27 Jul, 3:40 PM Wockhardt informs about newspaper publication 24 Jul, 1:52 PM Wockhardt informs about details of loss of certificate 21 Jul, 4:50 PM Wockhardt - Quaterly Results 26 May, 5:25 PM Wockhardt - Quaterly Results 26 May, 5:25 PM Wockhardt - Quaterly Results 26 May, 5:25 PM Wockhardt informs about secretarial compliance report 23 May, 12:34 PM Wockhardt informs about disclosure 1 Apr, 3:44 PM Wockhardt informs about disclosure 1 Apr, 10:25 AM Wockhardt informs about closure of trading window 27 Mar, 5:08 PM Wockhardt planning to roll out two vaccines within year from UK-based facility 27 Feb, 12:46 PM Wockhardt informs about conference call 24 Feb, 4:31 PM Wockhardt - Quaterly Results 13 Feb, 3:15 PM Wockhardt - Quaterly Results 13 Feb, 3:15 PM Wockhardt - Quaterly Results 13 Feb, 3:15 PM Wockhardt informs about loss of share certificates 13 Dec, 5:17 PM Wockhardt informs about disclosure 19 Nov, 11:05 AM

Wockhardt Stock Price Analysis and Quick Research Report. Is Wockhardt an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Wockhardt and its performance over the period of time. Wockhardt stock price today is Rs 1233.4.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Wockhardt cash from the operating activity was Rs 188 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Wockhardt has a Debt to Equity ratio of 1.0039 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Wockhardt , the EPS growth was 15.3224 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Wockhardt has OPM of -3.11958405545927 % which is a bad sign for profitability.
     
  • ROE: Wockhardt have a poor ROE of -23.9773 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Wockhardt is Rs 1233.4. One can use valuation calculators of ticker to know if Wockhardt share price is undervalued or overvalued.
Last Updated on:
Brief about Wockhardt

Wockhardt Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Wockhardt Ltd. is a pharmaceutical company headquartered in Mumbai, India. It has a global presence with operations in the United States, Ireland, and other countries. The company is primarily engaged in the manufacturing and marketing of pharmaceutical and biotechnology products. Wockhardt’s product portfolio includes formulations, biopharmaceuticals, active pharmaceutical ingredients (APIs), and vaccines. The company is committed to providing affordable healthcare to patients worldwide.

Wockhardt Ltd. - Share Price

Wockhardt Ltd. is a listed company on the Indian stock exchanges with a market capitalization of over INR 2,000 crores. The company’s stock symbol is WOCKPHARMA. The share price of Wockhardt Ltd. has been volatile in the past, primarily due to fluctuations in the pharmaceutical industry and the company’s financial performance. As a long-term investor, it is essential to analyze the company's fundamentals before making an investment decision.

Wockhardt Ltd. - Balance Sheet

Wockhardt Ltd. publishes its balance sheet annually as part of its financial statements. The balance sheet provides a snapshot of the company's financial position at a specific point in time. It outlines the company’s assets, liabilities, and shareholder’s equity. Our website provides access to Wockhardt Ltd.'s annual reports, which include the balance sheet, as a downloadable PDF. Using our premium features, investors can calculate the company's fair value using tools like the DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and the DuPont Analysis.

Wockhardt Ltd. - Annual Report

Wockhardt Ltd. releases an annual report every fiscal year that provides a comprehensive overview of the company's operations. The report includes a detailed analysis of the company's financial performance, achievements, and future plans. Our website offers Wockhardt Ltd.'s annual reports as downloadable PDFs, enabling investors to analyze the company's fundamental metrics.

Wockhardt Ltd. - Dividend

Wockhardt Ltd. has declared dividends in the past, although the frequency and amount have varied. As a long-term investor, it is essential to evaluate the company's dividend history and its commitment to future dividend payments. Our pre-built screening tools allow investors to analyze the company's dividend history and yield to determine the potential for dividend income.

Wockhardt Ltd. - Quarterly Results

Wockhardt Ltd. publishes its quarterly results as part of its financial reporting obligations. The quarterly results provide insights into the company's financial performance over a specific period. Our website provides access to Wockhardt Ltd.'s quarterly results as a downloadable PDF. Investors can use our premium features to calculate the company's fair value using tools like the DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and the DuPont Analysis.

Wockhardt Ltd. - Stock Price

Wockhardt Ltd.'s stock price can be accessed through our website or other financial websites. The stock price reflects the current market sentiment towards the company and is influenced by various factors like the company's financial performance, industry trends, and the economic environment. As a long-term investor, it is essential to evaluate the company's fundamentals before making an investment decision.

Wockhardt Ltd. - Price Chart

Wockhardt Ltd.'s price chart provides a visual representation of the company's stock price movement over a specific period. The chart can be accessed through our website or other financial websites. It is essential to analyze the company's price chart in conjunction with the fundamental metrics to make a sound investment decision.

Wockhardt Ltd. - News

Wockhardt Ltd. is a listed company, and its stock price is subject to market news and events. Our website provides access to real-time news and alerts related to the company. Investors can use our pre-built screening tools to analyze the company's news flow and its impact on the stock price.

Wockhardt Ltd. - Concall Transcripts

Wockhardt Ltd. conducts conference calls with analysts to discuss the company's financial performance and future plans. The conference call transcripts provide a comprehensive overview of the company's operations and can be accessed through our website as a downloadable PDF.

Wockhardt Ltd. - Investor Presentations

Wockhardt Ltd. presents investor presentations from time to time to discuss its financial performance and future plans. The presentations can be accessed through our website as a downloadable PDF. Investors can use the presentations to gain insights into the company's operations and management's vision for the future.

Wockhardt Ltd. - Promoters

Wockhardt Ltd.'s promoters are the founding family of the company. The promoters have a significant shareholding in the company and play an active role in the company's operations. It is essential to analyze the promoters' background, shareholding, and role in the company before making an investment decision.

Wockhardt Ltd. - Shareholders

Wockhardt Ltd.'s shareholder base includes institutional and retail investors. The company has a strong track record of corporate governance and ensures that the interests of all shareholders are protected. It is essential to analyze the company's shareholder base and its voting patterns in shareholder meetings.

In conclusion, Wockhardt Ltd. is a leading pharmaceutical company committed to providing affordable healthcare to patients worldwide. As a long-term investor, it is essential to evaluate the company's fundamentals, analyze its financial performance, and monitor industry trends before making an investment decision. Our website provides access to Wockhardt Ltd.'s annual reports, concall transcripts, investor presentations, and other critical information to facilitate informed investment decisions.

Read More
X